Watch a video about Steve, an Optune user. Learn how Steve manages his treatment while enjoying his favorite activities. Watch a video about Steve, an Optune user ...

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today results from a retrospective post-hoc analysis of its phase 3 pivotal EF-14 trial data showing that increased compliance ...

New flexible arrays are lighter, thinner and designed to improve comfort for Optune Gio users ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug ...

As a particularly aggressive brain tumor, it almost goes without saying that glioblastomas are scary things. Fortunately, patients are benefiting from a new technology that has only been available to ...

Novocure has gained clearance from the US Food and Drug Administration (FDA) for the new head flexible electrode (HFE) transducer arrays for use with Optune Gio, a wearable for treating adults with ...

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced the launch of MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home without ...

(RTTNews) - Novocure (NVCR) announced the FDA approved new Head Flexible Electrode transducer arrays for use with Optune Gio for the treatment of adult patients with glioblastoma multiforme. Novocure ...

As a result, Optune users experience very little in the way of side effects. That's a highly attractive advantage when compared to other cancer treatments like chemotherapy and radiation. When ...

ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced the launch of MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home without ...